Company intelligence / Profile preview

RLL

Lutherville, Maryland, United States

Ownership: Private
Development stage: Other

Overview

RLL is developing AOH1996, a first‑in‑class oral small‑molecule chemotherapy licensed from City of Hope that targets a cancer‑specific variant of proliferating cell nuclear antigen (PCNA); it has shown preclinical efficacy across multiple solid tumor types and is currently being evaluated in an ongoing Phase 1 trial in patients with recurrent solid tumors at City of Hope.[2][4]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

City of Hope

Beyond the preview

Go deeper on RLL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLL.

Explore the full profile